Non-Small Cell Lung Cancer
Conditions
Brief summary
This is a multicenter, single arm, phase II study evaluating efficacy in terms of RR in a cohort of NSCLC with MET amplification or MET exon 14 skipping mutation pre-treated or not with MET inhibitors.
Detailed description
The study population will include NSCLC patients with MET amplification or MET exon 14 skipping mutation pre-treated or not with MET inhibitors. Elegible NSCLC patients with MET exon 14 skipping mutations or MET amplification will be treated with open label orally cabozantinib 60 mg/daily, cycles each 28 days. Disease evaluation will be performed every two months (8 weeks). Patients will be treated with cabozantinib until disease progression, unacceptable toxicity or patient refusal.Treatment will be continued until disease progression, unacceptable toxicity or patient refusal. Treatment beyond disease progression is allowed if considered appropriate by the investigator.
Interventions
DRUGCabozantinib
Patients will be treated with cabozantinib 60 mg/daily (cycles each 28 days) until progression, toxicity or patient refusal.
Sponsors
Fondazione Ricerca Traslazionale
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Citological or histological diagnosis of non-small-cell-lung cancer (NSCLC) stage III B (not suitable for local treatments with curative intent) or stage IV. 2. Tissue samples available for MET analysis (archivial tissue or tissue collected at study entry); patients without archival tumor tissue or refusing new biopsy at study entry, are eligible if MET mutation is detected in cf-DNA 3. Presence of MET mutations (exon 14 skipping mutation ONLY) detected in tissue or cf-DNA at the local lab or in the central lab or MET amplification (MET/CEP7 ratio \> 2.2) detected in the central lab ONLY. 4. Measurable disease according to RECIST criteria version 1.1 5. At least 1 prior line of standard therapy (chemotherapy and/ or immunotherapy) 6. Performance status 0-1 (ECOG) 7. Age ≥18 years 8. Patients potentially fertile using adequate methods of contraception in order to avoid childbearing. Contraceptive methods must be respected by male and female patients and their partners during study treatment period and at least 4 months after completing therapy 9. Adequate hematologic and end organ function, defined by the following laboratory results obtained within 14 days prior to enrollment: 1. ANC ≥ 1500 cells/μL without granulocyte colony-stimulating factor support 2. Platelet count ≥ 100,000/μL without transfusion 3. Hemoglobin ≥ 9.0 g/dL Patients may be transfused to meet this criterion 4. AST, ALT, and alkaline phosphatase ≤ 2.5 × ULN, with the following exceptions: * Patients with documented liver metastases: AST and/or ALT ≤ 5 × ULN * Patients with documented liver or bone metastases: alkaline phosphatase ≤ 5 × ULN. 5. Serum bilirubin ≤ 1.25 × ULN 6. Patients with known Gilbert disease who have serum bilirubin level ≤ 3 × ULN may be enrolled 7. Calculated creatinine clearance (CRCL) ≥ 45 mL/min or calculated CRCL must be ≥ 60 mL/min 10. Patient compliance to the study procedure 11. Written informed consent
Exclusion criteria
1. Tissue sample not available in patients without MET exon 14 skipping mutation detected in cf-DNA 2. No possibility to assess MET status 3. Absence of any measurable disease according to RECIST criteria 4. Co-existence of driver events, including EGFR mutations, KRAS mutations, ALK rearrangements or ROS-1 rearrangements 5. No prior therapy 6. Concomitant chemotherapy or immunotherapy or radiotherapy 7. Symptomatic brain metastasis 8. Uncontrolled significant inter-current or recent illness, including cardio-vascular disorders and gastro-intestinal disorders 9. Major surgery within 2 months before first dose of study treatment 10. Concomitant anti-coagulation with oral anti-coagulants or plated inhibitors 11. History of significant bleeding, trachea-bronchial tree/major blood vessels invading tumors, cavity pulmonary lesions and GI disorders associated with a risk of perforation or fistula formation 12. Diagnosis of another cancer in the last 3 years, except for in situ carcinoma of cervix, breast and bladder or skin carcinoma (squamous or basalioid) 13. Pregnancy or breastfeeding
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Response Rate (RR) (complete + partial responses) | Up to 36 months | RR will be evaluated by investigators according to Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1. Partial and complete responses will be confirmed following RECIST criteria 1.1. Disease evaluation will be performed every two months (8 weeks). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression free survival (PFS) | Up to 36 months | Disease evaluation will be performed every 8 weeks |
| Overall survival (OS) | Up to 36 months | Disease evaluation will be performed every 8 weeks |
| Disease Control Rate (DCR: stable disease + partial response + complete response) | Up to 36 months | Disease evaluation will be performed every 8 weeks |
| Exploratory biomarkers | Up to 36 months | At baseline, at the first disease evaluation and at progression of disease a blood sample will be collected for biomarkers analyses |
Countries
Italy
Contacts
Primary ContactFederico Cappuzzo
Backup ContactLorenza Landi
Outcome results
None listed